AbbVie FY2025 EPS Estimate Decreased by Cantor Fitzgerald

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of AbbVie in a research report issued to clients and investors on Monday, November 3rd. Cantor Fitzgerald analyst C. Gould now forecasts that the company will post earnings per share of $10.66 for the year, down from their prior estimate of $10.82. Cantor Fitzgerald has a “Overweight” rating and a $250.00 price objective on the stock. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the firm earned $3.00 EPS. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.

A number of other equities analysts have also weighed in on ABBV. Guggenheim lifted their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. UBS Group set a $251.00 target price on AbbVie in a report on Friday, October 3rd. BMO Capital Markets lifted their price target on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. boosted their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday. Finally, Wall Street Zen upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $238.05.

AbbVie Trading Up 0.5%

NYSE ABBV opened at $216.96 on Wednesday. AbbVie has a 1 year low of $163.81 and a 1 year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The company has a market capitalization of $383.27 billion, a PE ratio of 103.31, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a fifty day moving average of $222.84 and a 200 day moving average of $201.84.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is presently 524.24%.

Insider Activity at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.25% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Brighton Jones LLC lifted its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Abound Financial LLC purchased a new position in shares of AbbVie during the 1st quarter worth $30,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of AbbVie by 6.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,653 shares of the company’s stock worth $3,489,000 after acquiring an additional 1,077 shares during the period. Finally, Brown Financial Advisory boosted its position in shares of AbbVie by 58.9% during the 1st quarter. Brown Financial Advisory now owns 3,051 shares of the company’s stock valued at $639,000 after acquiring an additional 1,131 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.